Market research
AZRX AzurRx BioPharma Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 34M
- P/E ratio
- Not available
- Analyst target
- 16
- Dividend yield
- 0.0%
- Beta
- 1.51
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US33749P1012
- Market cap
- 34M
- P/E ratio
- Not available
- Analyst target
- 16
- Dividend yield
- 0.0%
- Beta
- 1.51
About
About AzurRx BioPharma Inc
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is based in Boca Raton, Florida.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AZRX discussion.
5 years, 4 months ago
AzurRx BioPharma, Inc is currently in a long term downtrend where the price is trading 20.3% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
AzurRx BioPharma, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 1257.7% to $-17M since the same quarter in the previous year.
Finally, its free cash flow fell by 82.2% to $-6M since the same quarter in the previous year.
Based on the above factors, AzurRx BioPharma, Inc gets an overall score of 1/5.